SalvaRx Group Plc

The SalvaRx Group is a drug discovery and development company focused on immune-oncology; SalvaRx invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies. The SalvaRx Group was founded by Drs. Ian Walters and Rob Kramer, two former Bristol-Myers Squibb drug developers with a history of championing immune-oncology and developing immune-oncology therapeutics. In 2015, SalvaRx made its first investment in iOx Therapeutics, a University of Oxford spin-out that is developing a compounds that stimulate Natural Killer T Cells.